Biotech | August 25, 2021
Carbogen Amcis AG signs co-investment agreement
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
